REFERENCES

• World Health Organization.International Classification of Diseases, 10th revision (ICD-10). Geneva, Switzerland: World Health Organization;2010
   Google Scholar
• American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders, 4th edition. Text Revision. Washington, DC: American Psychiatric Publishing;2000
   Google Scholar
• American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA: American Psychiatric Publishing;2013
   Google Scholar
• SchuckitMA.Treatment of opioid-use disorders.N Engl J Med.2016375435736827464203
   PubMed Web of Science ®Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2016: Trends and Developments. Available at: http:// www.emcdda.europa.eu/publications/edr/trends-developments/2014. Published May 2016. Accessed June 2017.
   Google Scholar
• PelesE.SchreiberS.AdelsonM.15-Year survival and retention of patients in a general hospital-affiliated methadone maintenance treatment (MMT) center in Israel.Drug Alcohol Depend.20101072-314114819914783
   PubMed Web of Science ®Google Scholar
• DegenhardtL.CharlsonF.MathersB.et alThe global epidemiology and burden of opioid dependence: results from the Global Burden of Disease 2010 study.Addiction.201410981320133324661272
   PubMed Web of Science ®Google Scholar
• United Nations Office on Drugs and Crime.World Drug Report 2016. New York, NY: United Nations2016
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2014: Trends and Developments. Available at: http:// www.emcdda.europa.eu/publications/edr/trends-developments/2014. Published May 2014. Accessed June 2017.
   Google Scholar
• JonesCM.LoganJ.GladdenRM.BohmMK.Vital signs: demographic and substance use trends among heroin users - United States, 2002-2013.MMWR Morb Mortal VJkly Rep.20156426719725
   PubMed Web of Science ®Google Scholar
• Center for Behavioral Health Statistics and Quality.Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15-4927, NSDUH Series H-50);2015
   Google Scholar
• National Institute on Drug Abuse. Overdose death rates. Available at: https://www.drugabuse.gov/related-topics/trends-statistics/overdosedeath-rates. Revised January 2017. Accessed March 31, 2017
   Google Scholar
• ImtiazS.ShieldKD.FischerB.RehmJ.Harms of prescription opioid use in the United States.Subst Abuse Treat Prev Policy.201494325352167
   PubMed Web of Science ®Google Scholar
• KampmanK.JarvisM.American Society of Addiction Medicine (ASAM) National Practice guideline for the use of medications in the treatment of addiction involving opioid use.J Addict Med.20159535836726406300
   PubMed Web of Science ®Google Scholar
• MammenK.BellJ.The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.Expert Opin Pharmacother200910152537254419708849
   PubMed Web of Science ®Google Scholar
• MattickRP.BreenC.KimberJ.DavoliM.Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.Cochrane Database Syst Rev.20142CD002207
   PubMed Web of Science ®Google Scholar
• SoykaM.KranzlerHR.van den BrinkW.KrystalJ.MollerHJ.KasperS.The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence.World J Biol Psychiatry201112316018721486104
   PubMed Web of Science ®Google Scholar
• SoykaM.TraderA.KlotscheJ.et alSix-year mortality rates of patients in methadone and buprenorphine maintenance therapy: results from a nationally representative cohort study.J Clin Psychopharmacol.201131567868021881461
   PubMed Web of Science ®Google Scholar
• ConnockM.Juarez-GarciaA.JowettS.et alMethadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.Health Technol Assess.20071191171, iii-iv
   PubMed Web of Science ®Google Scholar
• KakkoJ.SvanborgKD.KreekMJ.HeiligM.1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial.Lancet.2003361935866266812606177
   PubMed Web of Science ®Google Scholar
• HserYl.EvansE.GrellaC.LingW.AnglinD.Long-term course of opioid addiction.Harv Rev Psychiatry2015232768925747921
   PubMed Web of Science ®Google Scholar
• HserYl.EvansE.HuangD.et alLong-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial.Addiction.2016111469570526599131
   PubMed Web of Science ®Google Scholar
• BeckT.HaasenC.VertheinU.et alMaintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone.Addiction.2014109461762624304412
   PubMed Web of Science ®Google Scholar
• StrangJ.GroshkovaT.UchtenhagenA.et alHeroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addictiondagger.Br J Psychiatry2015207151426135571
   PubMed Web of Science ®Google Scholar
• KleberHD.WeissRD.AntonRF Jr.et alTreatment of patients with substance use disorders, second edition. American Psychiatric Association.Am J Psychiatry20071644 suppl5123
   PubMed Web of Science ®Google Scholar
• New South Wales Department of Health.Opioid treatment program: clinical guidelines for methadone and buprenorphine treatment. Sydney, Australia: NSW Government2011
   Google Scholar
• Lingford-HughesAR.WelchS.PetersL.NuttDJ.BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP.J Psychopharmacol.201226789995222628390
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for the psychosocial assisted pharmacological treatment of opioid dependence. Geneva, Switzerland: World Health Organization; 2009
   Google Scholar
• YokellMA.ZallerND.GreenTC.RichJD.Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review.Curr Drug Abuse Rev.201141284121466501
   PubMedGoogle Scholar
• WalshSL.PrestonKL.StitzerML.ConeEJ.BigelowGE.Clinical pharmacology of buprenorphine: ceiling effects at high doses.Clin Pharmacol Ther.19945555695808181201
   PubMed Web of Science ®Google Scholar
• WalshSL.JuneHL.SchuhKJ.PrestonKL.BigelowGE.StitzerML.Effects of buprenorphine and methadone in methadone-maintained subjects.Psychopharmacology (Berl).199511932682767675960
   PubMed Web of Science ®Google Scholar
• AuriacombeM.FatseasM.DubernetJ.DaulouedeJP.TignolJ.French field experience with buprenorphine.Am J Addict.200413suppl 1S17S2815204673
   PubMed Web of Science ®Google Scholar
• QuaglioG.PattaroC.GerraG.et alBuprenorphine in maintenance treatment: experience among Italian physicians in drug addiction centers.Am J Addict.201019322223020525028
   PubMed Web of Science ®Google Scholar
• GundersonEW.LevinFR.RomboneMM.VosburgSK.KleberHD.Improving temporal efficiency of outpatient buprenorphine induction.Am J Addict201120539740421838837
   PubMed Web of Science ®Google Scholar
• SaxonAJ.LingW.HillhouseM.et alBuprenorphine/naloxone and methadone effects on laboratory indices of liver health: a randomized trial.Drug Alcohol Depend.20131281-2717622921476
   PubMed Web of Science ®Google Scholar
• LiebschutzJM.CrooksD.HermanD.et alBuprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial.JAMA Intern Med.201417481369137625090173
   PubMed Web of Science ®Google Scholar
• ChiangCN.HawksRL.Pharmacokinetics of the combination tablet of buprenorphine and naloxone.Drug Alcohol Depend.2003702 supplS39S4712738349
   PubMedGoogle Scholar
• KakkoJ.GronbladhL.SvanborgKD.et alA stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial.Am J Psychiatry2007164579780317475739
   PubMed Web of Science ®Google Scholar
• LofwallMR.WalshSL.A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.J Addict Med.20148531532625221984
   PubMed Web of Science ®Google Scholar
• SchottenfeldRS.PakesJR.OlivetoA.ZiedonisD.KostenTR.Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse.Arch Gen Psychiatry19975487137209283506
   PubMed Web of Science ®Google Scholar
• SoykaM.ZinggC.KollerG.KuefnerH.Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study.Int J Neuropsychopharmacol.200811564165318205978
   PubMed Web of Science ®Google Scholar
• GreenwaldMK.JohansonCE.MoodyDE.et alEffects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers.Neuropsychopharmacology200328112000200912902992
   PubMed Web of Science ®Google Scholar
• PintoH.MaskreyV.SwiftL.RumballD.WagleA.HollandR.The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment.J Subst Abuse Treat201039434035220817384
   PubMed Web of Science ®Google Scholar
• SoykaM.BackmundM.SchmidtP.ApeltS.Buprenorphine-naloxone treatment in opioid dependence and risk of liver enzyme elevation: results from a 12-month observational study.Am J Addict201423656356925251050
   PubMed Web of Science ®Google Scholar
• KaoDP.HaigneyMC.MehlerPS.KrantzMJ.Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration.Addiction.201511091468147526075588
   PubMed Web of Science ®Google Scholar
• TimkoC.SchultzNR.CucciareMA.VittorioL.Garrison-DiehnC.Retention in medication-assisted treatment for opiate dependence: a systematic review. JAddict Dis.20163512235
   Google Scholar
• HserYl.SaxonAJ.HuangD.et alTreatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.Addiction.20141091798723961726
   PubMed Web of Science ®Google Scholar
• BurnsL.GisevN.LarneyS.et alA longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.Addiction.2015110464665525516077
   PubMed Web of Science ®Google Scholar
• SoykaM.StrehleJ.RehmJ.BuhringerG.WittchenHU.Six-year outcome of opioid maintenance treatment in heroin-dependent patients: results from a naturalistic study in a nationally representative sample.Eur Addict Res.20172329710528376505
   PubMed Web of Science ®Google Scholar
• FareedA.VayalapalliS.CasarellaJ.DrexlerK.Effect of buprenorphine dose on treatment outcome.J Addict Dis.201231181822356665
   PubMed Web of Science ®Google Scholar
• JacobsP.AngA.HillhouseMP.et alTreatment outcomes in opioid dependent patients with different buprenorphine/naloxone induction dosing patterns and trajectories.Am J Addict.201524766767526400835
   PubMed Web of Science ®Google Scholar
• VolkowND.CollinsFS.The role of science in addressing the opioid crisis.N Engl J Med. 2017 May 13. Epub ahead of print.
   Google Scholar
• RosenthalRN.LingW.CasadonteP.et alBuprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone.Addiction.2013108122141214923919595
   PubMed Web of Science ®Google Scholar
• RosenthalRN.LofwallMR.KimS.ChenM.BeebeKL.VocciFJ.Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a randomized clinical trial.JAMA.2016316328229027434441
   PubMed Web of Science ®Google Scholar
• LingW.CasadonteP.BigelowG.et alBuprenorphine implants for treatment of opioid dependence: a randomized controlled trial.JAMA.2010304141576158320940383
   PubMed Web of Science ®Google Scholar
• WalshSL.ComerSD.LofwallMR.et alEffect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: a randomized clinical trial.JAMA Psychiatry. 2017 Jun 22. Epub ahead of print.
   Google Scholar
• McCance-KatzE.Drug-Drug Interactions in Opioid Therapy. 7th ed. London, UK: PCM Healthcare Ltd;2012
   Google Scholar
• KaranLD.McCance-KatzE.ZajicekA.Pharmacokinetics and pharmacodynamic principles. In: Ries RK, Fiellin DA, Miller SC, eds.Principles of Addiction Medicine. 4th ed. Philadelphia, PA: Wolters Kluwer/ Lippincott Williams & Wilkins;20096784
   Google Scholar
• GruberVA.McCance-KatzEF.Methadone, buprenorphine, and street drug interactions with antiretroviral medications.Curr HIVIAIDS Rep.201073152160
   PubMedGoogle Scholar
• Saber-TehraniAS.BruceRD.AlticeFL.Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence.Am J Drug Alcohol Abuse.201137111121247284
   PubMed Web of Science ®Google Scholar
• DegenhardtL.BucelloC.MathersB.et alMortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies.Addiction.20111061325121054613
   PubMed Web of Science ®Google Scholar
• RuddRA.AleshireN.ZibbellJE.GladdenRM.Increases in drug and opioid overdose deaths-United States, 2000-2014.MMWR Morb Mortal WklyRep.20166450-5113781382
   PubMed Web of Science ®Google Scholar
• AuriacombeM.FranquesP.TignolJ.Deaths attributable to methadone vs buprenorphine in France.JAMA.200128514511150107
   PubMed Web of Science ®Google Scholar
• BellJR.ButlerB.LawranceA.BateyR.SalmelainenP.Comparing overdose mortality associated with methadone and buprenorphine treatment.Drug Alcohol Depend.20091041-2737719443138
   PubMed Web of Science ®Google Scholar
• KintzP.Deaths involving buprenorphine: a compendium of French cases.Forensic Sci int.20011211-2656911516889
   PubMed Web of Science ®Google Scholar
• PaniPP.TroguE.MaremmaniI.PaciniM.QTc interval screening for cardiac risk in methadone treatment of opioid dependence.Cochrane Database Syst Rev.2013 6CD00893923787716
   PubMed Web of Science ®Google Scholar
• BjornaasMA.BekkenAS.OjlertA.et alA 20-year prospective study of mortality and causes of death among hospitalized opioid addicts in Oslo.BMC Psychiatry20088818271956
   PubMed Web of Science ®Google Scholar
• PirnayS.BorronSW.GiudicelliCP.TourneauJ.BaudFJ.RicordelI.A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths.Addiction.200499897898815265095
   PubMed Web of Science ®Google Scholar
• SoykaM.ApeltSM.LiebM.WittchenHU.One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: a nationally representative cohort study in 2694 patients.J Clin PsychopharmacoL200626665766017110826
   PubMed Web of Science ®Google Scholar
• CornishR.MacleodJ.StrangJ.VickermanP.HickmanM.Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database.BMJ.2010341c547520978062
   PubMed Web of Science ®Google Scholar
• LiebM.WittchenHU.PalmU.ApeltSM.SiegertJ.SoykaM.Psychiatric comorbidity in substitution treatment of opioid-dependent patients in primary care: prevalence and impact on clinical features.Heroin Addict RelatClin Probl.2010124516
   Web of Science ®Google Scholar
• GossopM.MarsdenJ.Assessment and treatment of opiate problems.Baillieres Clin Psychiatry.19962445459
   Google Scholar
• SimpsonDD.SellsSB.Effectiveness of treatment for drug abuse: an overview of the DARP Research Program.Adv Alcohol Subst Abuse198222729
   Google Scholar
• SimpsonDD.SellsSBe.Opioid Addiction and Treatment: A 12-year FollowUp. Malabar, FL: Robert E. Kreiger1990
   Google Scholar
• HubbardRL.MarsdenME.RachalJV.HarwoodHJ.CavanaughER.GinzburgHM.Drug Abuse Treatment: A National Study of Effectiveness. Chapel Hill, NC: The University of North Carolina Press;1989
   Google Scholar
• DutraL.StathopoulouG.BasdenSL.LeyroTM.PowersMB.OttoMW.A meta-analytic review of psychosocial interventions for substance use disorders.Am J Psychiatry2008165217918718198270
   PubMed Web of Science ®Google Scholar
• AmatoL.MinozziS.DavoliM.VecchiS.FerriM.MayetS.Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence.Cochrane Database Syst Rev2004 4 CD00414715495081
   PubMedGoogle Scholar
• BerglundM.ThelanderS.JonssonE.Treating Alcohol and Drug Abuse: An Evidence Based Review. Weinheim, Germany: Wiley-VCH;2003
   Google Scholar
• DugoshK.AbrahamA.SeymourB.McLoydK.ChalkM.FestingerD.A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction.J Addict Med.20161029310326808307
   PubMed Web of Science ®Google Scholar
• DayE.MitchesonL.Psychosocial interventions in opiate substitution treatment services: does the evidence provide a case for optimism or nihilism?Addiction.201711281329133628044376
   PubMed Web of Science ®Google Scholar
• AmatoL.MinozziS.DavoliM.VecchiS.Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence.Cochrane Database Syst Rev.2011 10CD00414721975742
   PubMed Web of Science ®Google Scholar
• AmatoL.MinozziS.DavoliM.VecchiS.Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification.Cochrane Database Syst Rev.2011 9CD00503121901695
   PubMed Web of Science ®Google Scholar
• FiellinDA.BarryDT.SullivanLE.et alA randomized trial of cognitive behavioral therapy in primary care-based buprenorphine.Am J Med.2013126174.e1174.e17
   PubMed Web of Science ®Google Scholar
• LingW.HillhouseM.AngA.JenkinsJ.FaheyJ.Comparison of behavioral treatment conditions in buprenorphine maintenance.Addiction.2013108101788179823734858
   PubMed Web of Science ®Google Scholar
• MooreBA.BarryDT.SullivanLE.et alCounseling and directly observed medication for primary care buprenorphine maintenance: a pilot study.J Addict Med.20126320521122614936
   PubMed Web of Science ®Google Scholar
• SigmonSC.OchalekTA.MeyerAC.et alInterim buprenorphine vs. waiting list for opioid dependence.N Engl J Med.2016375252504250528002704
   PubMed Web of Science ®Google Scholar
• MattickRP.BreenC.KimberJ.DavoliM.Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.Cochrane Database Syst Rev.2009 3CD00220919588333
   PubMed Web of Science ®Google Scholar
• EvansE.LiL.MinJ.et alMortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10.Addiction.20151106996100525644938
   PubMed Web of Science ®Google Scholar
• HserYl.AnglinD.PowersK.A 24-year follow-up of California narcotics addicts.Arch Gen Psychiatry.19935075775848317951
   PubMed Web of Science ®Google Scholar
• NosykB.LiL.EvansE.et alUtilization and outcomes of detoxification and maintenance treatment for opioid dependence in publicly-funded facilities in California, USA: 1991-2012.Drug Alcohol Depend.201414314915725110333
   PubMed Web of Science ®Google Scholar
• KarpJF.ButtersMA.BegleyAE.et alSafety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults.J Clin Psychiatry.2014758e785e79325191915
   PubMed Web of Science ®Google Scholar